Cytotoxic lymphocyte antigen-4 (CTLA-4) blockade plus vaccine as a combination therapy strategy to promote the immune response to cancer has demonstrated similar toxicities to anti-CTLA-4 monotherapy. As anti-CTLA-4 therapy has demonstrated clinical efficacy, continued exploration and optimization is warranted and must include investigations of combination strategies and management of adverse events.
- Padmanee Sharma
- Christopher Logothetis